PharmaEssentia USA Appoints Dr. Barry Flannelly as Independent Director
PharmaEssentia USA Appoints Dr. Barry Flannelly as Independent Director, Strengthening Leadership Amid Expanding Global Ambitions PharmaEssentia USA Corporation, a wholly owned subsidiary of PharmaEssentia Corporation (TWSE: 6446), today announced the…
TFDA Approves Orphan Drug Designation for Tinostamustine in Malignant Glioma
FDA Grants Orphan Drug Designation to Tinostamustine for the Treatment of Malignant Glioma Purdue Pharma L.P. (“Purdue”) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan…
CuraSen Reports Positive Phase 1 Data for CuraAX (CST-3056) at 2025 AAS Symposium
CuraSen Therapeutics Presents Positive Phase 1 Data Demonstrating Safety, Pharmacokinetics, and Pharmacodynamics of CuraAX (CST-3056) at the 2025 American Autonomic Society International Symposium CuraSen Therapeutics, Inc., a privately held biopharmaceutical…
Revvity, MDIC, and NIST Launch Somatic Cancer Reference Standards to Ensure Diagnostic Accuracy
Revvity Launches Next-Generation Somatic Cancer Reference Standards in Collaboration with MDIC and NIST Revvity, Inc. today announced the release of its new, highly characterized Mimix™ Geni™ somatic cancer reference standards,…
City Therapeutics Submits Clinical Trial Application for CITY-FXI
City Therapeutics Submits Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic Targeting Factor XI for the Treatment of Thromboembolic Diseases City Therapeutics, Inc., a pioneering biopharmaceutical company focused on…
Kardigan Reports Positive Phase 2 Results for Ataciguat in Aortic Stenosis
Kardigan Showcases Positive Phase 2 Data for Ataciguat in Moderate Calcific Aortic Valve Stenosis at AHA Scientific Sessions 2025 Kardigan, a cardiovascular-focused biotechnology company working to modernize drug development for…
Onchilles Pharma Publishes ELANE Pathway Study, Advances N17350 With New Funding
Onchilles Pharma Publishes Landmark ELANE Pathway Study, Advances N17350 Toward Clinical Development With New Financing and Strategic Clinical Expertise Onchilles Pharma, a privately held biotechnology company developing a new class…
CrossBridge Bio Named “Best Drug Developer” at 2025 World ADC Awards
CrossBridge Bio Awarded “Best Drug Developer” at the 2025 World ADC Awards, Celebrating Breakthrough Innovation in Dual-Payload ADCs CrossBridge Bio, an emerging biopharmaceutical innovator specializing in the development of next-generation…
Aulos Bioscience Phase 2 Results Show Imneskibart Activity in Melanoma and NSCLC
Aulos Bioscience Unveils Encouraging New Phase 2 Data Highlighting Imneskibart’s Clinical Activity in Melanoma and Non–Small Cell Lung Cancer Aulos Bioscience, a clinical-stage immuno-oncology company advancing next-generation immune-modulating therapies, has…
FASENRA Delays Disease Flares in Phase III HES Trial
AstraZeneca’s FASENRA Demonstrates Statistically Significant Clinical Benefit in Phase III NATRON Trial for Hypereosinophilic Syndrome AstraZeneca has announced positive full results from its pivotal Phase III NATRON clinical trial evaluating…
Indapta Highlights Clinical Activity of Allogeneic NK Therapy in R/R Multiple Myeloma
Indapta Therapeutics Showcases Promising Clinical Activity of IDP-023 Allogeneic g-NK Cell Therapy in Relapsed/Refractory Multiple Myeloma at SITC 2025 Indapta Therapeutics, Inc., a privately held, clinical-stage biotechnology company focused on…
Synthekine Reports Positive Early Phase 1 Results for STK-012 Combo in First-Line PD-L1-Negative NSCLC
Synthekine Unveils Encouraging Early Clinical Results for STK-012 in Combination Therapy for First-Line PD-L1–Negative Non-Squamous NSCLC at SITC 2025 Synthekine Inc., a biotechnology company advancing a new generation of engineered…